Defect in DNA damage response (DDR) is a common feature of cancer cells, which regulates tumor growth and therapeutic response. Recently, the approval of immune checkpoint blockade (ICB) for tumors with defective mismatch repair has paved the way for investigating the role of other DDR defects in sensitizing cancer to ICB therapy. Despite great progress in understanding DDR pathways, the mechanisms that link DDR defects and ICB response remain incompletely understood. Further, the clinical activity of ICB in patients with DDR defective tumors has not been well described. Here, we discuss recent studies demonstrating that biomarkers in DDR pathways may serve as potential predictors to guide the selection of patients for ICB therapy. A better understanding of the relationship between deficiency in DDR and response to ICB would facilitate efforts in optimizing the efficacy of immunotherapy.

中文翻译：

---

DNA修复缺陷在预测免疫治疗反应中的作用。

DNA损伤反应（DDR）的缺陷是癌细胞的一个共同特征，它调节肿瘤的生长和治疗反应。最近，对具有错配修复缺陷的肿瘤的免疫检查点封锁（ICB）的批准为研究其他DDR缺陷在使癌症对ICB治疗敏感方面的作用铺平了道路。尽管在了解DDR途径方面取得了长足的进步，但将DDR缺陷与ICB响应联系起来的机制仍未完全了解。此外，ICB在DDR缺陷肿瘤患者中的临床活性尚未得到很好的描述。在这里，我们讨论了最近的研究，这些研究表明DDR通路中的生物标记物可以作为潜在的预测指标，指导选择ICB治疗的患者。